The Europe Chronic Disease Management Market would witness market growth of 11.4% CAGR during the forecast period (2022-2028).
Studies that have examined how disease management programmes affect costs have generally shown evidence that the programmes decrease health care utilization, but not necessarily expenditures. For instance, Fireman et al. found that a provider-based programme run by the Permanente Medical Group of Northern California enhanced the utilization of underutilized services and enhanced physiological indicators of health, but that it did not produce overall savings due to the increased cost of the disease management programme, that included considerable efforts to alter the way primary care was delivered in addition to coaching components.
People with chronic illnesses typically need more medical services, such as doctor visits, hospital stays, and prescription medications. Health plans, the government, and employers are all looking for ways to lower health care usage expenses as a result of an escalation in the number of people who live longer with chronic health conditions and increasing health-care prices. One strategy that tries to improve care while lowering the expense of caring for the chronically ill is disease management.
The Department of Health has been the central government agency primarily in charge of establishing policies for the English healthcare and social care systems. The particular roles & responsibilities of the Department have changed as a result of the 2012 Health and Social Care Act, moving away from direct obligation for delivering the NHS to one that now offers strategic direction, serves as caretaker for the health and care system, evolves national policies, and offer guidance. NHS England, a recently formed institution, is now in charge of delivering care services and the NHS.
The Germany market dominated the Europe Chronic Disease Management Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $657.7 million by 2028.The UK market is anticipated to grow at a CAGR of 10.5% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 12.3% during (2022 - 2028).
Based on Type, the market is segmented into Solutions and Services. Based on End User, the market is segmented into Healthcare Providers, Healthcare Payers and Others. Based on Disease Type, the market is segmented into Diabetes, Cardiovascular diseases, Asthma, Chronic obstructive pulmonary disorders, Cancer and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Chronic Disease Management Market will Hit $9.9 Billion by 2028, at a CAGR of 11.7%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Infosys Limited, ExlService Holdings, Inc., Health Catalyst, Inc., AllScripts Healthcare Solutions, Inc., Koninklijke Philips N.V., Cognizant Technology Solutions Corporation, Casenet, LLC, Cedar Gate Technologies, Clinical Excellence, Inc., and Altruista Health, Inc.
By Type
By End User
By Disease Type
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 